Calculate the Finnegan NAS to assess neonatal opioid withdrawal severity. Includes 24-item scoring, treatment thresholds, pharmacologic management guidance, and category breakdowns.
The Finnegan Neonatal Abstinence Score (NAS) Calculator implements the standard 24-item clinical assessment tool for evaluating neonatal opioid withdrawal syndrome (NOWS). Developed by Loretta Finnegan in 1975, the scoring system quantifies withdrawal severity across three domains — CNS disturbances, metabolic/vasomotor/respiratory signs, and gastrointestinal disturbances — to guide pharmacologic treatment decisions.
Neonatal abstinence syndrome affects an estimated 7 per 1,000 hospital births in the United States, reflecting the broader opioid epidemic. Infants exposed to opioids in utero (from maternal opioid use disorder, methadone maintenance, or buprenorphine treatment) typically develop withdrawal symptoms within 24–72 hours of birth (longer for methadone). The Finnegan score is assessed every 2–4 hours by trained nursing staff, with treatment initiated when scores consistently exceed defined thresholds.
Pharmacologic treatment (morphine or methadone as first-line, with phenobarbital or clonidine as adjuncts) is indicated when scores reach ≥8 on three consecutive assessments or ≥12 on two consecutive assessments. The goal is to control withdrawal symptoms while minimizing medication exposure, typically weaning over 1–4 weeks. Non-pharmacologic interventions (low stimulation, swaddling, skin-to-skin care) are foundational for all affected neonates regardless of score.
The Finnegan NAS provides objective, reproducible withdrawal assessment that standardizes treatment decisions across providers. Without standardized scoring, treatment initiation varies widely. Consistent scoring also enables monitoring of treatment response and guides medication weaning. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
Finnegan NAS = Sum of all 24 item scores Scoring categories: • CNS (10 items): cry (0–3), sleep (0–3), Moro reflex (0–3), tremors disturbed/undisturbed (0–3 each), muscle tone (0–2), excoriation (0–1), myoclonus (0–3), seizures (0–5) • Metabolic/Vasomotor/Respiratory (9 items): sweating (0–1), fever (0–2), yawning (0–1), nasal stuffiness/sneezing/flaring (0–2), RR (0–2) • GI (5 items): sucking (0–1), feeding (0–2), vomiting (0–2), stool consistency (0–3) Maximum score: ~38 Treatment threshold: ≥8 (×3) or ≥12 (×2)
Result: NAS = 10 — Moderate withdrawal. Score ≥8 on 3 consecutive assessments triggers pharmacologic treatment.
A score of 10 with tremors (disturbed = 2), high-pitched cry (2), sleep <2 hours (2), excessive sucking (1), sneezing (1), loose stools (2) across categories. This meets the single-score criterion of ≥8 and would trigger treatment if confirmed on 2 more consecutive assessments. First-line treatment: morphine 0.04–0.08 mg/kg q3–4h. Continue swaddling, low stimulation, and frequent small feeds.
The Finnegan NAS was developed in 1975 at Thomas Jefferson University Hospital and has been the most widely used NAS scoring tool for nearly 50 years. The modified Finnegan score (Finnegan & Kaltenbach, 1986) is the most common variant, reducing items from 31 to 24. Alternatives include: the Lipsitz tool (11 items, simpler), the MOTHER NAS scale (designed for clinical trials), and the newly developed ESC (Eat, Sleep, Console) functional assessment. The trend in NAS management is moving toward simpler, function-based assessments and away from complex scoring systems.
Evidence-based non-pharmacologic interventions form the foundation of NAS care. Key components: 1) Low-stimulation environment (dim lights, quiet, minimal handling), 2) Swaddling in flexed position, 3) Skin-to-skin / kangaroo care, 4) Breastfeeding when not contraindicated, 5) Rooming-in with mother, 6) Pacifier for non-nutritive sucking, 7) Small, frequent feedings with high-calorie formula if needed, 8) Gentle rocking or vibration. Meta-analyses show these interventions collectively reduce pharmacotherapy rates by 30–50%. Some centers using comprehensive non-pharmacologic bundles report pharmacotherapy rates below 20%.
NAS neonates require ongoing follow-up after discharge: developmental screening at regular intervals (increased risk of developmental delays, behavioral issues), hearing assessment (ototoxicity monitoring if aminoglycosides were used), weight monitoring (feeding difficulties may persist), and connection to early intervention services. Children with NAS history are at modestly increased risk for attention difficulties, language delays, and visual/motor problems, though outcomes are difficult to separate from the effects of the postnatal environment. Parental support services and home visiting programs improve long-term outcomes.
Timing depends on the specific opioid: heroin-exposed neonates show symptoms within 24–48 hours. Methadone-exposed neonates may not show symptoms until 48–72 hours (sometimes up to 5–7 days due to methadone's long half-life). Buprenorphine-exposed neonates typically present within 24–48 hours but often with milder symptoms. Delayed onset (>5 days) can occur with long-acting opioids. Scoring should start within 2 hours of birth for at-risk infants and continue for at least 72–96 hours even if initial scores are low.
First-line: Morphine (0.04–0.1 mg/kg q3–4h, dose titrated to score) or methadone (0.05–0.1 mg/kg q6–12h) are opioid replacement therapies that treat withdrawal at the receptor level. Adjuncts: Phenobarbital (for seizures or refractory withdrawal), clonidine (alpha-2 agonist, addresses autonomic symptoms). Buprenorphine sublingual is emerging as an alternative with potentially shorter treatment course. Goal: stabilize at the minimum effective dose, then wean by 10–20% per dose reduction every 24–48 hours based on sustained low scores.
Average hospitalization for pharmacologically treated NAS is 17–25 days (highly variable). Treatment duration depends on: the maternal substance (methadone-exposed infants have longer withdrawal than heroin or buprenorphine), polydrug exposure (benzodiazepines, SSRIs, nicotine complicate withdrawal), initial severity, and institutional protocols. Non-pharmacologically managed infants average 5–10 days. The trend toward eat-sleep-console (ESC) rather than Finnegan scoring has reduced average treatment duration and length of stay in many centers.
ESC is a newer, simplified assessment method that is increasingly replacing the Finnegan scoring system. It asks three questions: Can the baby eat ≥1 oz per feed? Can the baby sleep ≥1 hour undisturbed? Can the baby be consoled within 10 minutes? If all three answers are "yes," pharmacotherapy is not needed regardless of traditional NAS signs. Studies show ESC reduces pharmacotherapy rates by 30–50% and hospital length of stay by 5–10 days compared to Finnegan-based protocols. It emphasizes non-pharmacologic care and parent involvement.
For opioid-dependent pregnant women, medically supervised opioid maintenance therapy (methadone or buprenorphine) is the standard of care — abrupt opioid cessation during pregnancy risks fetal distress, preterm labor, and stillbirth. Buprenorphine maintenance produces less severe NAS than methadone in many studies. Breastfeeding, rooming-in, and non-pharmacologic care are preventive in the sense that they reduce NAS severity and need for treatment. Prenatal care, maternal nutrition, avoiding polydrug use, and stable dosing all improve outcomes.
Several substance classes can cause neonatal withdrawal: benzodiazepines (seizures, irritability, feeding difficulty — may have delayed onset), SSRIs/SNRIs (poor neonatal adaptation syndrome in ~30%, usually mild), alcohol (rare fetal alcohol withdrawal), barbiturates (similar to opioid withdrawal), cannabis (mild, controversial), and nicotine (irritability, poor feeding, tremors). Polydrug exposure is common and can complicate the clinical picture. The Finnegan score was designed for opioid withdrawal but some items overlap with other withdrawal syndromes.